Literature DB >> 18458055

Morantel allosterically enhances channel gating of neuronal nicotinic acetylcholine alpha 3 beta 2 receptors.

Tse-Yu Wu1, Caleb M Smith, Steven M Sine, Mark M Levandoski.   

Abstract

We studied allosteric potentiation of rat alpha3beta2 neuronal nicotinic acetylcholine receptors (nAChRs) by the anthelmintic compound morantel. Macroscopic currents evoked by acetylcholine (ACh) from nAChRs expressed in Xenopus laevis oocytes increase up to 8-fold in the presence of low concentrations of morantel (< or =10 microM); the magnitude of the potentiation depends on both agonist and modulator concentrations. It is noteworthy that the potentiated currents exceed the maximum currents achieved by saturating (millimolar) concentrations of agonist. Studies of macroscopic currents elicited by prolonged drug applications (100-300 s) indicate that morantel does not increase alpha3beta2 receptor activity by reducing slow (> or =1 s) desensitization. Instead, using outside-out patch-clamp recordings, we demonstrate that morantel increases the frequency of single-channel openings and alters the bursting characteristics of the openings in a manner consistent with enhanced channel gating; these results quantitatively explain the macroscopic current potentiation. Morantel is a very weak agonist alone, but we show that the classic competitive antagonist dihydro-beta-erythroidine inhibits morantel-evoked currents noncompetitively, indicating that morantel does not bind to the canonical ACh binding sites.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18458055      PMCID: PMC2587017          DOI: 10.1124/mol.107.044388

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  45 in total

1.  Refined structure of the nicotinic acetylcholine receptor at 4A resolution.

Authors:  Nigel Unwin
Journal:  J Mol Biol       Date:  2005-01-25       Impact factor: 5.469

Review 2.  Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors.

Authors:  D Colquhoun
Journal:  Br J Pharmacol       Date:  1998-11       Impact factor: 8.739

3.  Determinants of competitive antagonist sensitivity on neuronal nicotinic receptor beta subunits.

Authors:  S C Harvey; C W Luetje
Journal:  J Neurosci       Date:  1996-06-15       Impact factor: 6.167

4.  Influence of subunit composition on desensitization of neuronal acetylcholine receptors at low concentrations of nicotine.

Authors:  C P Fenster; M F Rains; B Noerager; M W Quick; R A Lester
Journal:  J Neurosci       Date:  1997-08-01       Impact factor: 6.167

5.  Pharmacology of the nicotinic acetylcholine receptor from fetal rat muscle expressed in Xenopus oocytes.

Authors:  J C Cooper; O Gutbrod; V Witzemann; C Methfessel
Journal:  Eur J Pharmacol       Date:  1996-08-15       Impact factor: 4.432

6.  Congenital myasthenic syndrome caused by decreased agonist binding affinity due to a mutation in the acetylcholine receptor epsilon subunit.

Authors:  K Ohno; H L Wang; M Milone; N Bren; J M Brengman; S Nakano; P Quiram; J N Pruitt; S M Sine; A G Engel
Journal:  Neuron       Date:  1996-07       Impact factor: 17.173

Review 7.  Modes of action of anthelmintic drugs.

Authors:  R J Martin
Journal:  Vet J       Date:  1997-07       Impact factor: 2.688

8.  Unusual pharmacology of (+)-tubocurarine with rat neuronal nicotinic acetylcholine receptors containing beta 4 subunits.

Authors:  A B Cachelin; G Rust
Journal:  Mol Pharmacol       Date:  1994-12       Impact factor: 4.436

Review 9.  The diversity of GABAA receptors. Pharmacological and electrophysiological properties of GABAA channel subtypes.

Authors:  W Hevers; H Lüddens
Journal:  Mol Neurobiol       Date:  1998-08       Impact factor: 5.590

10.  Physostigmine and galanthamine: probes for a novel binding site on the alpha 4 beta 2 subtype of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells.

Authors:  E F Pereira; M Alkondon; S Reinhardt; A Maelicke; X Peng; J Lindstrom; P Whiting; E X Albuquerque
Journal:  J Pharmacol Exp Ther       Date:  1994-08       Impact factor: 4.030

View more
  12 in total

1.  The different ways through which specificity works in orthosteric and allosteric drugs.

Authors:  Ruth Nussinov; Chung-Jung Tsai
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 2.  Orthosteric and allosteric potentiation of heteromeric neuronal nicotinic acetylcholine receptors.

Authors:  Jingyi Wang; Jon Lindstrom
Journal:  Br J Pharmacol       Date:  2017-03-20       Impact factor: 8.739

Review 3.  Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations.

Authors:  Dustin K Williams; Jingyi Wang; Roger L Papke
Journal:  Biochem Pharmacol       Date:  2011-05-14       Impact factor: 5.858

4.  Specificity determinants of allosteric modulation in the neuronal nicotinic acetylcholine receptor: a fine line between inhibition and potentiation.

Authors:  Laura C Cesa; Colin A Higgins; Steven R Sando; Dennis W Kuo; Mark M Levandoski
Journal:  Mol Pharmacol       Date:  2011-11-07       Impact factor: 4.436

Review 5.  Levamisole receptors: a second awakening.

Authors:  Richard J Martin; Alan P Robertson; Samuel K Buxton; Robin N Beech; Claude L Charvet; Cédric Neveu
Journal:  Trends Parasitol       Date:  2012-05-17

6.  Subunit interfaces contribute differently to activation and allosteric modulation of neuronal nicotinic acetylcholine receptors.

Authors:  Caitlin A Short; Angela T Cao; Molly A Wingfield; Matthew E Doers; Emily M Jobe; Nan Wang; Mark M Levandoski
Journal:  Neuropharmacology       Date:  2014-12-05       Impact factor: 5.250

Review 7.  Discovery of potent positive allosteric modulators of the α3β2 nicotinic acetylcholine receptor by a chemical space walk in ChEMBL.

Authors:  Justus J Bürgi; Mahendra Awale; Silvan D Boss; Tifany Schaer; Fabrice Marger; Juan M Viveros-Paredes; Sonia Bertrand; Jürg Gertsch; Daniel Bertrand; Jean-Louis Reymond
Journal:  ACS Chem Neurosci       Date:  2014-03-04       Impact factor: 4.418

Review 8.  Effects of neuronal nicotinic acetylcholine receptor allosteric modulators in animal behavior studies.

Authors:  Anshul A Pandya; Jerrel L Yakel
Journal:  Biochem Pharmacol       Date:  2013-05-31       Impact factor: 5.858

9.  The positive allosteric modulator morantel binds at noncanonical subunit interfaces of neuronal nicotinic acetylcholine receptors.

Authors:  Seungmae Seo; Jonathan T Henry; Amanda H Lewis; Nan Wang; Mark M Levandoski
Journal:  J Neurosci       Date:  2009-07-08       Impact factor: 6.167

10.  Glutamine 57 at the complementary binding site face is a key determinant of morantel selectivity for {alpha}7 nicotinic receptors.

Authors:  Mariana Bartos; Kerry L Price; Sarah C R Lummis; Cecilia Bouzat
Journal:  J Biol Chem       Date:  2009-06-08       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.